"The US patent is for the method of treating ischemia by administering pooled allogeneic mesenchymal stromal cells," Stempeutics Research said in a statement. Critical Limb Ischemia is a severe blockage in the arteries which results in reduced blood flow which in turn may result in poor quality of life.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Nt7dYh
via IFTTT
0 comments:
Post a Comment